Cancer Detection Rates in Targeted Transperineal MRI-TRUS Elastic Fusion-guided Prostate Biopsies Performed Under Local Anesthesia

Background/Aim: The aim of this study was to evaluate the cancer detection rate (CDR) using magnetic resonance imaging-transrectal ultrasound (MRI-TRUS) fusion-guided transperineal targeted biopsy (TB). Patients and Methods: We included 401 consecutive patients, which 161 were biopsy-naïve. All underwent prebiopsy bi-parametric MRI; patients with positive MRI [prostate imaging reporting data system (PI-RADS≥3)] TB. Biopsy-naïve TB systematic biopsies (SBs). MRI-negative SBs. Clinically significant prostate (csPCa) defined as ISUP ≥2. added value SB an upgrade from a negative or 1 in csPCa SB. Results: median (interquartile range) age 69 (range=63-74) years, PSA 6.9 (range=4.5-11) ng/ml. overall CDR 65%, occurring 48%. In cases PI-RADS 5, 91%, 77%. 2%. Conclusion: Transperineal MRI-TRUS fusion yield high CDR.